Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres

Current Oncology

Volumn 18, Issue 3, 2011, Pages 119-125

  Madarnas, Y ^a,b   Dent, S F ^c   Husain, S F ^a   Robinson, A ^d   Alkhayyat, S ^e   Hopman, W M ^b   Verreault, J L ^c   Vandenberg, T ^e  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d Northeastern Ontario Regional Cancer Centre   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Breast cancer; Febrile neutropenia; FEC D chemotherapy; Growth factor; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; RETROSPECTIVE STUDY;

EID: 79959317567     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i3.751     Document Type: Article

References (23)

1. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2009. Toronto, ON: Canada Cancer Society; 2009.
2. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
3. Fisher B, Carbone P, Economou SG, et al. l-Phenylalanine mustard (l-pam) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975;292:117-22.
4. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-717.
5. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;8:2651-8.
6. Bonneterre J, Roché H, Kerbrat P, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005;23:2686-93.
7. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010;1:22-36.
8. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11:1-144.
9. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxanecontaining regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004;6:372-80.
10. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;:CD004421.
11. Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the fnclcc pacs 01 trial. J Clin Oncol 2006;24:5664-71.
12. Duff J, Leather H, Walden EO, LaPlant KD, George TJ Jr. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 2010;102:702-5.
13. Vlahakes GJ. The value of phase 4 clinical testing. N Engl J Med 2006;354:413-15.
14. Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA 2008;300:2177-9.
15. Avorn J. In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-21.
16. Meyer RM. Generalizing the results of cancer clinical trials. J Clin Oncol 2010;28:187-9.
17. Soong D, Haj R, Leung MG, Myers R, Higgins B, Myers J, et al. High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol 2009;27:e101-2.
18. Crawford J, Dale D, Lyman G. Chemotherapy-induced neutropenia. Risks, consequences, and new directions for its management. Cancer 2004;100:228-37.
19. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 2009;27:2170-6.
20. Fairey AS, Courneya KS, Field CJ, Mackey JR. Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. Cancer 2002;94:539-51.
21. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;2:316-22.
22. Morrison VA. An overview of the management of infection and febrile neutropenia in patients with cancer. Support Cancer Ther 2005;2:88-94.
23. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. V.1.2010. Fort Washington, PA: nccn; 2010.